Overview
The aim of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS9531 injection compared with placebo in adolescents with obesity
Eligibility
Inclusion Criteria:
- Male or female subjects who are aged ≥12 years and \<18 years at the time of signing the informed consent;
- At screening, the BMI meets the obesity criteria according to "WS/T586-2018 Screening Criteria for Overweight and Obesity in School-age Children and Adolescents";
- Subjects who have maintained a controlled diet and exercise for at least 12 weeks prior to screening, with no more than a 5% decrease in BMI (as reported by the subject, parent, or legal guardian);
Exclusion Criteria:
- Presence of clinically significant lab results at screening visit;
- Uncontrollable hypertension;
- Medical history or illness that affects your weight;
- History of diabetes;
- Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening;
- Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness;
- Use of drugs or treatments that may have caused significant weight gain or loss within the 3 months prior to screening;
- Pre-adolescent participants (Tanner phase I);
- Patients with blood donation or blood loss ≥400 mL or receiving blood transfusion within 3 months before screening.
- Surgery is planned during the tria;
- Mentally incapacitated or speech-impaired subjects are unable to fully understand or participate in the test process；
- In the investigator's judgment, there are circumstances that affect subject safety or any other conditions that interfere with the evaluation of the test results.
